Early synaptic dysfunction in Parkinson's disease: Insights from animal models

Movement Disorders

Volumn 31, Issue 6, 2016, Pages 802-813

  Schirinzi, Tommaso ^a   Madeo, Graziella ^a   Martella, Giuseppina ^a,b   Maltese, Marta ^a   Picconi, Barbara ^b   Calabresi, Paolo ^b,c   Pisani, Antonio ^a,b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Parkinson's disease; Presymptomatic stage; Substantia nigra; Synaptopathy

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMPA RECEPTOR; DJ 1 PROTEIN; LEUCINE RICH REPEAT KINASE 2; OXIDOPAMINE; PARKIN;

BASAL GANGLION; BRAIN CELL; CELL BODY; CELL MIGRATION; CHOLINERGIC NERVE CELL; DISEASE COURSE; DISEASE MODEL; DOPAMINERGIC NERVE CELL; ENDOCYTOSIS; EXOCYTOSIS; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENETIC MODEL; HUMAN; LEWY BODY; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVE FIBER TRANSPORT; NEUROIMAGING; NEUROPATHOLOGY; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIMARY MOTOR CORTEX; PRIORITY JOURNAL; REVIEW; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS COMPACTA; SYNAPTIC TRANSMISSION; SYNAPTOPATHY; ANIMAL; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY; SYNAPSE;

ANIMALS; DISEASE MODELS, ANIMAL; PARKINSON DISEASE; SYNAPSES;

EID: 84971222619     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26620     Document Type: Review

References (119)

1. Bezard E, Dovero S, Prunier C, et al. Gross CE Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 2011;21:6853-6861.
2. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003;39:889-909.
3. Hilker R, Schweitzer K, Coburger S, et al. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005;62:378-382.
4. Morrish PK, Sawle GV, Brooks DJ. Regional changes in [18F]dopametabolism in the striatum in Parkinson's disease. Brain 1996;119:2097-2103
5. Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease. Neuron 2010;66:646-661.
6. Wishart TM, Parson SH, Gillingwater TH. Synaptic vulnerability in neurodegenerative disease. J Neuropathol Exp Neurol 2006;65:733-739.
7. Busche MA, Konnerth A. Neuronal hyperactivity--A key defect in Alzheimer's disease? Bioessays 2015;37:624-632.
8. Crabtree GW, Gogos JA. Synaptic plasticity, neural circuits, and the emerging role of altered short-term information processing in schizophrenia. Front Synaptic Neurosci 2014;6:28.
9. Brose N, O'Connor V, Skehel P. Synaptopathy: dysfunction of synaptic function? Biochem Soc Trans 2010;38:443-444.
10. Hunn BH, Cragg SJ, Bolam JP, et al. Impaired intracellular trafficking defines early Parkinson's disease. Trends Neurosci 2015;38:178-188.
11. Scarffe LA, Stevens DA, Dawson VL, et al. Parkin and PINK1: much more than mitophagy. Trends Neurosci 2014;37:315-324.
12. Jiang H, Jackson-Lewis V, Muthane U, et al. Adenosine receptor antagonists potentiate dopamine receptor agonist-induced rotational behavior in 6-hydroxydopamine-lesioned rats. Brain Res 1993;613:347-351.
13. Chan H, Paur H, Vernon AC, et al. Neuroprotection and functional recovery associated with decreased microglial activation following selective activation of mGluR2/3 receptors in a rodent model of Parkinson's disease. Parkinsons Dis 2010; pii: 190450.
14. Ilijic E, Guzman JN, Surmeier DJ. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol Dis 2011;43:364-371.
15. Bjorklund LM, Sanchez-Pernaute R, Chung S, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci U S A 2002;99:2344-2349.
16. Kirik D, Georgievska B, Burger C, et al. Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc Natl Acad Sci U S A 2002;99:4708-4713.
17. Roy NS, Cleren C, Singh SK, et al. Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med 2006;12:1259-1268.
18. Calabresi P, Picconi B, Tozzi A, et al. Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 2007;30:211-219.
19. Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 2003;6:501-506.
20. Paillé V, Picconi B, Bagetta V, et al. Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. J Neurosci 2010;30:14182-14193.
21. Ingham CA, Hood SH, Arbuthnott GW. Spine density on neostriatal neurons changes with 6-hydroxydopamine lesions and with age. Brain Res 1989;503:334-338.
22. Stephens B, Mueller AJ, Shering AF, et al. Evidence of a breakdown of corticostriatal connections in Parkinson's disease. Neuroscience 2005;132:741-754.
23. Zaja-Milatovic S, Milatovic D, Schantz AM, et al. Dendritic degeneration in neostriatal medium spiny neurons in Parkinson disease. Neurology 2005;64:545-547.
24. Smith Y, Villalba R. Striatal and extrastriatal dopamine in the basal ganglia: an overview of its anatomical organization in normal and Parkinsonian brains. Mov Disord 2008;23(Suppl 3):S534-S547.
25. Smith Y, Villalba RM, Raju DV. Striatal spine plasticity in Parkinson's disease: pathological or not? Parkinsonism Relat Disord 2009;15(Suppl 3):S156-S161.
26. Toy WA, Petzinger GM, Leyshon BJ, et al. Treadmill exercise reverses dendritic spine loss in direct and indirect striatal medium spiny neurons in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. Neurobiol Dis 2014;63:201-209.
27. Villalba R. M., Lee H., Smith Y. Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys. Exp Neurol 2009;215:220-227.
28. Deutch AY, Colbran RJ, Winder DJ. Striatal plasticity and medium spiny neuron dendritic remodeling in parkinsonism. Parkinsonism Relat Disord 2007;13(Suppl 3):S251-S258.
29. Betarbet R, Greenamyre JT. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP. Exp Neurol 2004;189:393-403.
30. Ba M, Kong M, Yang H, et al. Changes in subcellular distribution and phosphorylation of GluR1 in lesioned striatum of 6-hydroxydopamine-lesioned and l-dopa-treated rats. Neurochem Res 2006;31:1337-1347.
31. Meredith GE, Sonsalla PK, Chesselet MF. Animal models of Parkinson's disease progression. Acta Neuropathol 2008;115:385-398.
32. Bezard E, Przedborski S. A tale on animal models of Parkinson's disease. Mov Disord 2011;26:993-1002.
33. Wersinger C, Vernier P, Sidhu A. Trypsin disrupts the trafficking of the human dopamine transporter by alpha-synuclein and its A30P mutant. Biochemistry 2004;43:1242-1253.
34. McLean PJ, Kawamata H, Ribich S, et al. Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. J Biol Chem 2000;275:8812-8816.
35. Spillantini MG, Schmidt ML, Lee VM, et al. Alpha-synuclein in Lewy bodies. Nature 1997;388:839-840.
36. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease Neurobiol Aging 2003;24:197-211.
37. Kramer ML, Schulz-Schaeffer WJ. Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. J Neurosci 2007;27:1405-1410.
38. Polymeropoulos MH, Lavedan C, Leroy E, et al. Mutation in the alpha synuclein gene identified in families with Parkinson's disease. Science 1997;276:2045-2047.
39. Krüger R, Kuhn W, Müller T, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 1998;18:106-108.
40. Singleton AB, Farrer M, Johnson J, et al. Alpha-synuclein locus triplication causes Parkinson's disease. Science 2003;302:841.
41. Zarranz JJ, Alegre J, Gómez-Esteban JC, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 2004;55:164-173.
42. Ross OA, Braithwaite AT, Skipper LM, et al. Genomic investigation of alpha-synuclein multiplication and Parkinsonism. Ann Neurol 2008;63:743-750.
43. Maries E, Dass B, Collier TJ, et al. The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev Neurosci 2003;4:727-738.
44. Tozzi A, Costa C, Siliquini S, et al. Mechanisms underlying altered striatal synaptic plasticity in old A53T-alpha synuclein overexpressing mice. Neurobiol Aging 2012;33:1792-1799.
45. Rafalovich IV, Melendez AE, Plotkin JL, Tanimura A, Zhai S, Surmeier DJ. Interneuronal Nitric Oxide Signaling Mediates Post-synaptic Long-Term Depression of Striatal Glutamatergic Synapses. Cell Rep 2015;13:1336-1342.
46. Calabresi P, Gubellini P, Centonze D, et al. A critical role of the nitric oxide/cGMP pathway in corticostriatal long-term depression. J Neurosci 1999;19:2489-499.
47. Tozzi A, de Iure A, Bagetta V, et al. Alpha-Synuclein Produces Early Behavioral Alterations Via Striatal Cholinergic Synaptic Dysfunction by Interacting with GluN2D N-Methyl-D-Aspartate Receptor Subunit. Biol Psychiatry 2015. pii: S0006-3223(15)00678-2.
48. Yavich L, Tanila H, Vepsäläinen S, et al. Role of alpha-synuclein in presynaptic dopamine recruitment. J Neurosci 2004;24:11165-11170.
49. Vargas KJ, Makani S, Davis T, et al. Synucleins regulate the kinetics of synaptic vesicle endocytosis. J Neurosci 2014;34:9364-9376.
50. Nemani VM, Lu W, Berge V, et al. Increased expression of alpha-synuclein reduces neurotransmitter release by inhibiting synaptic vesicle reclustering after endocytosis. Neuron 2010;65:66-79.
51. Janezic S, Threlfell S, Dodson PD, et al. Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc Natl Acad Sci U S A 2013;110:E4016-F4025.
52. Burré J, Sharma M, Südhof TC. Systematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activities. J Neurosci 2012;32:15227-15242.
53. Taylor TN, Potgieter D, Anwar S, et al. Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse. Neurobiol Dis 2014;62:193-207.
54. Lam HA, Wu N, Cely I, et al. Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human α-synuclein. J Neurosci Res 2011;89:1091-1102.
55. Lundblad M, Decressac M, Mattsson B, Björklund A. Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. Proc Natl Acad Sci U S A 2012;109:3213-3219.
56. Pacheco C, Aguayo LG, Opazo C. An extracellular mechanism that can explain the neurotoxic effects of α-synuclein aggregates in the brain. Front Physiol 2012;3:297.
57. Lee HJ, Bae EJ, Lee SJ. Extracellular α--synuclein-a novel and crucial factor in Lewy body diseases. Nat Rev Neurol 2014;10:92-98.
58. Jang A, Lee HJ, Suk JE, Jung JW, Kim KP, Lee SJ. Non-classical exocytosis of α-synuclein is sensitive to folding states and promoted under stress conditions. J Neurochem 2010;113:1263-1274.
59. Lee HJ, Baek SM, Ho DH, Suk JE, Cho ED, Lee SJ. Dopamine promotes formation and secretion of non-fibrillar α-synuclein oligomers. Exp Mol Med 2011;43:216-222.
60. Emmanouilidou E, Melachroinou K, Roumeliotis T, et al. Cell-produced alpha-synuclein is secreted in a calcium- dependent manner by exosomes and impacts neuronal survival. J Neurosci 2010; 30:6838-6851.
61. Diógenes MJ, Dias RB, Rombo DM, et al. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci 2012;32:11750-11762.
62. Kumari U, Tan EK. LRRK2 in Parkinson's disease: genetic and clinical studies from patients. FEBS J 2009;276:6455-6463.
63. Li JQ, Tan L, Yu JT. The role of the LRRK2 gene in Parkinsonism. Mol Neurodegener 2014;9:47.
64. Cookson MR, Dauer W, Dawson T, et al. The roles of kinases in familial Parkinson's disease. J Neurosci 2007;27:11865-11868.
65. West AB, Moore DJ, Biskup S, et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 2005;102:16842-16847.
66. West AB, Moore DJ, Choi C, et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 2007;16:223-232.
67. Lee S, Liu HP, Lin WY, et al. LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction. J Neurosci 2010;30:16959-16969.
68. Matta S, Van Kolen K, da Cunha R, et al. LRRK2 controls an EndoA phosphorylation cycle in synaptic endocytosis. Neuron 2012;75:1008-1021.
69. Li Y, Liu W, Oo TF, et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 2009;12:826-828.
70. Ng CH, Mok SZ, Koh C, et al. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci 2009;29:11257-11262.
71. Venderova K, Kabbach G, Abdel-Messih E, et al. Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. Hum Mol Genet 2009;18:4390-4404.
72. Lin TK, Liou CW, Chen SD, et al. Mitochondrial dysfunction and biogenesis in the pathogenesis of Parkinson's disease. Chang Gung Med J 2009;32:589-599.
73. Tong Y, Shen J. Alpha-synuclein and LRRK2: partners in crime. Neuron 2009;64:771-773.
74. Daher JP, Abdelmotilib HA, Hu X, et al. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration. J Biol Chem 2015;290:19433-19444.
75. Henderson JL, Kormos BL, Hayward MM, et al. Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2, 3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor. J Med Chem 2015;58:419-432.
76. Piccoli G, Condliffe SB, Bauer M, et al. LRRK2 controls synaptic vesicle storage and mobilization within the recycling pool. J Neurosci 2011;31:2225-2237.
77. Piccoli G, Onofri F, Cirnaru MD, et al. Leucine-rich repeat kinase 2 binds to neuronal vesicles through protein interactions mediated by its C-terminal WD40 domain. Mol Cell Biol 2014;34:2147-2161.
78. Parisiadou L, Yu J, Sgobio C, et al. LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity. Nat Neurosci 2014;17:367-376.
79. Beccano-Kelly DA, Volta M, Munsie LN, et al. LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory. Hum Mol Genet 2015 1;24:1336-1349.
80. Beccano-Kelly DA, Kuhlmann N, Tatarnikov I, et al. Synaptic function is modulated by LRRK2 and glutamate release is increased in cortical neurons of G2019S LRRK2 knock-in mice. Front Cell Neurosci 2014;8:301.
81. Tong Y, Pisani A, Martella G, et al. R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci U S A 2009;106:14622-14627.
82. Melrose HL, Dächsel JC, Behrouz B, et al. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis 2010;40:503-517.
83. Yue M, Hinkle KM, Davies P, et al. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis 2015;78:172-195.
84. Li X, Patel JC, Wang J, et al. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci 2010;30:1788-797.
85. Walker MD, Volta M, Cataldi S, et al. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging. J Parkinsons Dis 2014;4:483-498.
86. Trinh J, Farrer M. Advances in the genetics of Parkinson disease. Nat Rev Neurol 2013;9:445-454.
87. Madeo G, Martella G, Schirinzi T, et al. Aberrant striatal synaptic plasticity in monogenic parkinsonisms. Neuroscience 2012;211:126-35.
88. Dave KD, De Silva S, Sheth NP, et al. Phenotypic characterization of recessive gene knockout rat models of Parkinson's disease. Neurobiol Dis 2014;70:190-203.
89. Klein C, Lohmann-Hedrich K, Rogaeva E, et al. Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol 2007;6:652-662.
90. Eggers C, Schmidt A, Hagenah J, et al. Progression of subtle motor signs in PINK1 mutation carriers with mild dopaminergic deficit. Neurology 2010;74:1798-1805.
91. van Nuenen BF, van Eimeren T, van der Vegt JP, et al. Mapping preclinical compensation in Parkinson's disease: an imaging genomics approach. Mov Disord 2009;24:S703-S710.
92. Kitada T, Tomlinson JJ, Ao HS, et al. Considerations regarding the etiology and future treatment of autosomal recessive versus idiopathic Parkinson disease. Curr Treat Options Neurol 2012;14:230-240.
93. Madeo G, Schirinzi T, Martella G, et al. PINK1 heterozygous mutations induce subtle alterations in dopamine-dependent synaptic plasticity. Mov Disord 2014;29:41-53.
94. Johnson ME, Bobrovskaya L. An update on the rotenone models of Parkinson's disease: their ability to reproduce the features of clinical disease and model gene-environment interactions. Neurotoxicology 2015;46:101-116.
95. Martella G, Madeo G, Maltese M, et al. Exposure to low-dose rotenone precipitates synaptic plasticity alterations in PINK1 heterozygous knockout mice. Neurobiol Dis 2016;91:21-36.
96. Calabresi P, Ghiglieri V. "Lazy" nigrostriatal synapses in the heterozygous PINK1 mouse model of familial Parkinson's disease. Mov Disord 2014;29:11-14.
97. Kitada T, Pisani A, Porter DR, et al. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc Natl Acad Sci U S A 2007;104:11441-1446.
98. Hatcher JM, Pennell KD, Miller GW. Parkinson's disease and pesticides: a toxicological perspective. Trends Pharmacol Sci 2008;29:322-329.
99. Ramachandiran S, Hansen JM, Jones DP, Richardson JR, Miller GW. Divergent mechanisms of paraquat, MPP+, and rotenone toxicity: oxidation of thioredoxin and caspase-3 activation. Toxicol Sci 2007;95:163-171.
100. Nisticò R, Mehdawy B, Piccirilli S, Mercuri N. Paraquat- and rotenone-induced models of Parkinson's disease. Int J Immunopathol Pharmacol 2011;24:313-322.
101. George S, Mok SS, Nurjono M, et al. α-Synuclein transgenic mice reveal compensatory increases in Parkinson's disease-associated proteins DJ-1 and parkin and have enhanced α-synuclein and PINK1 levels after rotenone treatment. J Mol Neurosci 2010;42:243-254.
102. Mulcahy P, O'Doherty A, Paucard A, O'Brien T, Kirik D, Dowd E. The behavioural and neuropathological impact of intranigral AAV-α-synuclein is exacerbated by systemic infusion of the Parkinson's disease-associated pesticide, rotenone, in rats. Behav Brain Res 2013;243:6-15.
103. Zharikov AD, Cannon JR, Tapias V, et al. shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model. J Clin Invest 2015;125:2721-2735.
104. Bolam JP, Hanley JJ, Booth PA, Bevan MD. Synaptic organization of the basal ganglia. J Anat 2000:196:527-42.
105. Beeler JA, Petzinger G, Jakowec MW. The enemy within: propagation of aberrant corticostriatal learning to cortical function in Parkinson's disease. Front Neurol 2013;4:134.
106. Cazorla M, Kang UJ, Kellendonk C. Balancing the basal ganglia circuitry: a possible new role for dopamine D2 receptors in health and disease. Mov Disord 2015;30:895-903.
107. Calabresi P, Picconi B, Tozzi A, Ghiglieri V, Di Filippo M. Direct and indirect pathways of basal ganglia: a critical reappraisal. Nat Neurosci 2014:17:1022-1030.
108. Cazorla M, de Carvalho FD, Chohan MO, et al. Dopamine D2 receptors regulate the anatomical and functional balance of basal ganglia circuitry. Neuron 2014;81:153-164.
109. Cui G, Jun SB, Jin X, et al. Concurrent activation of striatal direct and indirect pathways during action initiation. Nature 2013;494:238-242.
110. Jin X, Tecuapetla F, Costa RM. Basal ganglia subcircuits distinctively encode the parsing and concatenation of action sequences. Nat Neurosci 2014;17:423-430.
111. Pisani A, Centonze D, Bernardi G, Calabresi P. Striatal synaptic plasticity: implications for motor learning and Parkinson's disease. Mov Disord 2005;20:395-402.
112. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann. Neurol 2006:59:559-562.
113. Bergman H, Wichmann T, DeLong M.R. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990;249:1436-1438.
114. Bezard E, Gross CE, Brotchie JM. Presymptomatic compensation in Parkinson's disease is not dopamine-mediated. Trends Neurosci 2003;26:215-221.
115. Gilio F, Currà A, Inghilleri M, Lorenzano C, Manfredi M, Berardelli A. Repetitive magnetic stimulation of cortical motor areas in Parkinson's disease: implications for the pathophysiology of cortical function. Mov Disord 2002;17:467-473.
116. Kishore A, Joseph T, Velayudhan B, Popa T, Meunier S. Early, severe and bilateral loss of LTP and LTD-like plasticity in motor cortex (M1) in de novo Parkinson's disease. Clin Neurophysiol 2012;123:822-828.
117. Bäumer T, Pramstaller PP, Siebner HR, et al. Sensorimotor integration is abnormal in asymptomatic Parkin mutation carriers: a TMS study. Neurology 2007;69:1976-1981.
118. Schneider SA, Talelli P, Cheeran BJ, Khan NL, Wood NW, Rothwell JC, Bhatia KP. Motor cortical physiology in patients and asymptomatic carriers of parkin gene mutations. Mov Disord 2008;23:1812-1819.
119. Helmich RC, Thaler A, van Nuenen BF, et al. Reorganization of corticostriatal circuits in healthy G2019S LRRK2 carriers. Neurology 2015;84:399-406.